Sirius Technologies announced the promising Phase 1 Clinical data from its Factor XI siRNA, a long-acting, next-generation anticoagulant for thrombosis disorder in September 2024. This breakthrough development marks as a significant milestone in the company’s efforts to revolutionize the treatment of blood clotting disorder.
The Phase 1 clinical demonstrated the safety, efficacy, and tolerability of factor XI siRNA in healthy volunteers. The data showed a significant and sustained reduction in Factor XI siRNA activity, which is a key driver of thrombus formation. Notably, the treatment was well-tolerated, with no significant adverse events reported.
Sirius Therapeutics innovative approach utilizes small interfering RNA technology to specifically targeted and reduced Factor XI siRNA activity. This targeted mechanism has the potential to provide safe alternative to traditional anticoagulants, which often carry as risk of bleeding complications. The promising results provided by the Phase 1 clinical development and bring hope to patients living with thrombosis disorder.
Coherent Market Insights states that, the global anticoagulant market is likely to experience a CAGR of 9.4% from 2022 to 2028. The market is projected to reach at a total of US$ 57,337.5 Million by 2028. In 2021, revenue is reached at US$ 30,773.1 million. Growth is being driven by the rising prevalence of chronic disease and increasing demand for anticoagulants globally.
There is an increasing demand for direct oral anticoagulants globally. The development and the introduction of direct oral anticoagulants will provide huge advancement in the field of anticoagulation. Growing adoption of novel oral anticoagulants in the developing countries is also anticipated for fueling demand for anticoagulants during the forecast period.
The adoption of anticoagulants is rising due to the growing usage of plasma in the pharmaceutical sector. These are also used in a range of clinical application. The range of applications include anti-tumor and anti-inflammatory to the protection of infectious diseases and the use of nano-carriers in drug delivery.
Moreover, rising focus on the development of novel anticoagulants and rising geriatric population will drive demand in the global anticoagulant market. The demand for improvised and non-invasive treatment are rising among the geriatric population which will lead to the increase demand for anticoagulants drugs globally. Factors including side effect and stringent government policies is associated to hamper market growth.
North America is poised to lead the global anticoagulant market during the forecast period. This is owing to increase in the incidence of chronic disease. Another reason for growth is the increasing adoption of novel oral anticoagulants in the region. Asia Pacific is projected to hold second largest position in the global anticoagulant market. This is due to the increase in the demand for anticoagulants in the region.
